- Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19
- Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19
- Eiger Bio to Participate in September 2020 Investor Conferences
- Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020
- Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
- Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
Eiger BioPharmaceuticals Inc (72C1:STU) closed at 7.75, 75.34% above the 52 week low of 4.42 set on Mar 17, 2020.
4.42Mar 17 202014.00Dec 27 2019
Markit short selling activity
|Market cap||269.91m USD|
|EPS (TTM)||-2.68 |
Data delayed at least 15 minutes, as of Oct 27 2020.